The Government of Canada invests in three teams of Canadian, Latin American and Caribbean scientists to help address unanswered questions about Zika virus

The spread of the Zika virus, which can cause devastating birth defects, has become a pressing public health issue in many countries. To this day, there is no vaccine to prevent and no medicine to treat Zika virus infections.

The Honourable Jane Philpott, Canada’s Minister of Health, announced a $3 million investment for Zika research in May 2016. GloPID-R members the Canadian Institutes of Health Research (CIHR) and the International Development Research Centre announced the names of the three teams of Canadian scientists who will collaborate with Latin American and Caribbean researchers to study the Zika virus.

Dr. Tom Hobman, from the University of Alberta, and his team will study how the Zika virus changes host cells during infection, with the goal of developing anti-viral therapies that can be used against the virus.

Dr. Keith Pardee, from the University of Toronto, and his team will test a new, low-cost tool to rapidly detect the presence of Zika virus in patients’ bodily fluids. The new diagnostic tool is designed to be used in remote, under-resourced locations and will be field tested in Ecuador, Brazil and Colombia. Current tests to diagnose Zika virus are time consuming and prone to false positives due to the possibility of a patient’s prior infection with other flaviviruses such as dengue.

Dr. Beate Sander, from Public Health Ontario, and her team will conduct field studies in Argentina, Colombia and Ecuador to better understand how the virus is spread from mosquitoes to humans, predict which areas in the region are most at risk and use computer simulations to assess the most effective intervention methods, including mosquito control measures and vaccine development.

Together, the international teams will create new knowledge to help develop diagnostics for Zika virus infection, understand the pathology caused by the virus, and ultimately prevent its transmission and morbidity.


“The health research community is only beginning to come to grips with this dangerous pathogen. These three research teams have the potential to shed new light on the Zika virus and save lives. They may come up with faster ways to test for infection, finding the best methods to stop the mosquitoes that spread the virus and develop therapies that are effective against Zika.”
Dr. Marc Ouellette, GloPID-R Vice Chair, Scientific Director, CIHR Institute of Infection and Immunity

“This initiative is key to helping protect populations in the Americas and Canada from Zika and other related diseases.  Zika is an insidious virus that exacts a severe burden on vulnerable groups in Latin America, particularly mothers, children and poor urban populations facing limited access to health services. This funding will allow leading researchers from Latin America and Canada to collaborate on cutting-edge research, discovering new knowledge and tools to more rapidly detect, respond and control the virus.”
Jean Lebel, President, International Development Research Centre, GloPID-R Member

Read the full article

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.